Nt-Probnp/Urine Hepcidin-25 Ratio and Cardiorenal Syndrome Type 1 in Patients with Severe Symptomatic Aortic Stenosis

Abstract

Background: This study aimed to determine whether novel and conventional cardiorenal biomarkers in patients before transcatheter aortic valve implantation may be associated with cardiorenal syndrome (CRS) type 1. Methods: Serum NT-proBNP and urine biomarkers (hepcidin-25, NGAL, IL-6) were measured before and 24 h after transcatheter aortic valve implantation. Results: 16/95 patients had CRS type 1. Those patients had longer length of stay in hospital (12.5 [9.0–16.0] vs 9.0 [8–12] days; p = 0.025) and were more frequently readmitted to hospital within 6 months after discharge (46.7 vs 15.6%; odds ratio: 4.7; 95% CI: 1.5–15.5; p = 0.007). The NT-proBNP/urine hepcidin-25 ratio (odds ratio: 2.89; 95% CI: 1.30–6.41; p = 0.009) was an independent modifier of CRS type 1. Conclusion: The NT-proBNP/urine hepcidin-25 ratio appears to be a modifier of risk of CRS type 1.

Keywords:

• acute kidney injury
• aortic stenosis
• biomarker ratio
• cardiorenal syndrome
• hepcidin
• NT-proBNP
• TAVI

Author contributions

Conceptualization: M Haase, A Haase-Fielitz. Methodology: J Nübel, M Hauptmann, A Haase-Fielitz, C Butter, M Hoffmeister, M Haase. Formal analysis and investigation: A Haase-Fielitz, M Haase, M Hauptmann, J Nübel. Writing (original draft preparation): A Haase-Fielitz, M Haase. Writing (review and editing): J Nübel, M Hauptmann, C Butter, M Hoffmeister, O Labrenz, K Jost, S Oess, J Schön, G Fritz. Funding acquisition and resources: J Nübel, A Haase-Fielitz, C Butter. Supervision: M Hoffmeister, C Butter, A Haase-Fielitz. All authors approved the final manuscript.

Acknowledgements

The authors thank J Friedrich for technical assistance.

Financial & competing interests disclosure

Funded by the Brandenburg Medical School (MHB) publication fund supported by DFG and by the Ministry of Science, Research and Cultural Affairs of the State of Brandenburg. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.